MiR-21 attenuates lipopolysaccharide-induced lipid accumulation and inflammatory response: Potential role in cerebrovascular disease

Lipids in Health and Disease

Volumn 13, Issue 1, 2014, Pages

  Feng, Jun ^a   Li, Antai ^b   Deng, Jingyuan ^a   Yang, Yanhua ^c   Dang, Lili ^d   Ye, Yuanpeng ^a   Li, Yuxin ^e   Zhang, Weiping ^b  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b Xi'an Central Hospital   (China)

^c Shaanxi People's Armed Police Corps Hospital   (China)

^d Department of Ophthalmology   (China)

^e XI'AN MEDICAL UNIVERSITY   (China)

Author keywords

Atherosclerosis; Foam cells; Inflammation; LPS; miR 21

Indexed keywords

ANIMALS; ATHEROSCLEROSIS; CELL LINE; CEREBROVASCULAR DISORDERS; FOAM CELLS; GENE EXPRESSION; INFLAMMATION MEDIATORS; LIPID METABOLISM; LIPOPOLYSACCHARIDES; MICE; MICRORNAS; NF-KAPPA B; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4;

EID: 84893710415     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-13-27     Document Type: Article

References (35)

1. Aortic arch plaques and risk of recurrent stroke and death. Di Tullio MR, Russo C, Jin Z, Sacco RL, Mohr J, Homma S, Circulation 2009 119 2376 2382 10.1161/CIRCULATIONAHA.108.811935 19380621
2. Targeting the unstable plaque in acute coronary syndromes. Thompson PL, Nidorf SM, Eikelboom J, Clin Ther 2013 35 1099 1107 10.1016/j.clinthera.2013.07. 332 23973042
3. Composition of carotid atherosclerotic plaque is associated with cardiovascular outcome a prognostic study. Hellings WE, Peeters W, Moll FL, Piers SR, van Setten J, Van der Spek PJ, de Vries J-PP, Seldenrijk KA, De Bruin PC, Vink A, Circulation 2010 121 1941 1950 10.1161/CIRCULATIONAHA.109.887497 20404256
4. Unstable angina and non-ST elevation myocardial infarction. Braunwald E, Am J Respir Crit Care Med 2012 185 924 932 10.1164/rccm.201109-1745CI 22205565
5. Inflammation in atherosclerosis. Libby P, Okamoto Y, Rocha VZ, Folco E, Circ J 2010 74 213 220 10.1253/circj.CJ-09-0706 20065609
6. Natural IgM specific for oxLDL protects murine macrophages from foam cells formation but lipopolysaccharide (LPS) disrupts the course by up-regulating the expression of Fc/μ receptor. Feng X, Heart 2011 97 58
7. Inflammation and atherosclerosis. Hansson GK, Robertson A-KL, Söderberg-Nauclér C, Annu Rev Pathol Mech Dis 2006 1 297 329 10.1146/annurev.pathol.1.110304.100100
8. Vinpocetine attenuates lipid accumulation and atherosclerosis formation. Cai Y, Li J-D, Yan C, Biochem Biophys Res Commun 2013 434 439 443 10.1016/j.bbrc.2013.03.092 23583194
9. Newby AC, Macrophages and Atherosclerosis Springer: Inflammation and Atherosclerosis 2012 331 352
10. Hepcidin destabilizes atherosclerotic plaque via overactivating macrophages after erythrophagocytosis. Li JJ, Meng X, Si HP, Zhang C, Lv HX, Zhao YX, Yang JM, Dong M, Zhang K, Liu SX, Arterioscler Thromb Vasc Biol 2012 32 1158 1166 10.1161/ATVBAHA.112.246108 22383698
11. Cyclooxygenase-2 inhibition increases lipopolysaccharide-induced atherosclerosis in mice. Gitlin JM, Loftin CD, Cardiovasc Res 2009 81 400 407 18948273
12. The protective effect of apamin on LPS/Fat-Induced atherosclerotic mice. Kim S-J, Park J-H, Kim K-H, Lee W-R, Pak SC, Han S-M, Park K-K, Evidence-Based Complement Altern Med 2012 2012 305454
13. Activated protein C improves lipopolysaccharide-induced cardiovascular dysfunction by decreasing tissular inflammation and oxidative stress. Nacira S, Meziani F, Dessebe O, Cattan V, Collin S, Montemont C, Gibot S, Asfar P, Ramaroson A, Regnault V, Crit Care Med 2009 37 246 255 10.1097/CCM. 0b013e318192fe4f 19112282
14. Apolipoprotein AI inhibits LPS-induced atherosclerosis in ApoE-/- mice possibly via activated STAT3-mediated upregulation of tristetraprolin. Yin K, Tang S-l, Yu X-h, Tu G-h, He R-f, Li J-f, Xie D, Gui Q-j, Fu Y-c, Jiang Z-s, Acta Pharmacol Sin 2013 34 837 846 10.1038/aps.2013.10 23564081
15. Melittin inhibits atherosclerosis in LPS/high-fat treated mice through atheroprotective actions. Kim S-J, Park J-H, Kim K-H, Lee W-R, Kim K-S, Park K-K, J Atheroscler Thromb 2011 18 1117 1126 10.5551/jat.8474 22008474
16. Adding fuel to fire: microRNAs as a new class of mediators of inflammation. Sheedy F, O'Neill L, Ann Rheum Dis 2008 67 ii50 iii55 19022814
17. Circulating microRNAs in patients with coronary artery diseasenovelty and significance. Fichtlscherer S, De Rosa S, Fox H, Schwietz T, Fischer A, Liebetrau C, Weber M, Hamm CW, Röxe T, Müller-Ardogan M, Circ Res 2010 107 677 684 10.1161/CIRCRESAHA.109.215566 20595655
18. microRNA regulation of inflammatory responses. O'Connell RM, Rao DS, Baltimore D, Annu Rev Immunol 2012 30 295 312 10.1146/annurev-immunol-020711- 075013 22224773
19. miR-147, a microRNA that is induced upon Toll-like receptor stimulation, regulates murine macrophage inflammatory responses. Liu G, Friggeri A, Yang Y, Park Y-J, Tsuruta Y, Abraham E, Proc Natl Acad Sci 2009 106 15819 15824 10.1073/pnas.0901216106 19721002
20. MicroRNA 21 in tissue injury and inflammation authors'retrospective. Sen CK, Roy S, Cardiovasc Res 2012 96 230 233 10.1093/cvr/cvs222
21. MicroRNA-21: from cancer to cardiovascular disease. Jazbutyte V, Thum T, Curr Drug Targets 2010 11 926 935 10.2174/138945010791591403 20415649
22. MicroRNA-21 in cardiovascular disease. Cheng Y, Zhang C, J Cardiovasc Transl Res 2010 3 251 255 10.1007/s12265-010-9169-7 20560046
23. miR-21, miR-210, miR-34a, and miR-146a/b are up-regulated in human atherosclerotic plaques in the tampere vascular study. Raitoharju E, Lyytikäinen L-P, Levula M, Oksala N, Mennander A, Tarkka M, Klopp N, Illig T, Kähönen M, Karhunen PJ, Atherosclerosis 2011 219 211 217 10.1016/j.atherosclerosis.2011.07.020 21820659
24. Lipopolysaccharide promotes lipid accumulation in human adventitial fibroblasts via TLR4-NF-κB pathway. Wang J, Si Y, Wu C, Sun L, Ma Y, Ge A, Li B, Lipids Health Dis 2012 11 1 9 10.1186/1476-511X-11-1 22221411
25. Lipopolysaccharide stimulation of RAW 264.7 macrophages induces lipid accumulation and foam cell formation. Funk JL, Feingold KR, Moser AH, Grunfeld C, Atherosclerosis 1993 98 67 82 10.1016/0021-9150(93)90224-I 8457252 (Pubitemid 23010425)
26. Tolllike receptor 4 in atherosclerosis. Li H, Sun B, J Cell Mol Med 2007 11 88 95 10.1111/j.1582-4934.2007.00011.x 17367503 (Pubitemid 46439627)
27. Expression of toll-like receptors in human atherosclerotic lesions A possible pathway for plaque activation. Edfeldt K, Swedenborg J, Hansson GK, Yan Z-q, Circulation 2002 105 1158 1161 11889007 (Pubitemid 34225814)
28. LPS/TLR4 signal transduction pathway. Lu Y-C, Yeh W-C, Ohashi PS, Cytokine 2008 42 145 151 10.1016/j.cyto.2008.01.006 18304834
29. Toll like receptor 4 in atherosclerosis and plaque destabilization. den Dekker WK, Cheng C, Pasterkamp G, Duckers HJ, Atherosclerosis 2010 209 314 320 10.1016/j.atherosclerosis.2009.09.075 19900676
30. MicroRNAs in the atheroclerotic plaque. Raitoharju E, Oksala N, Lehtimäki T, Clin Chem 2013
31. Lack of toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Michelsen KS, Wong MH, Shah PK, Zhang W, Yano J, Doherty TM, Akira S, Rajavashisth TB, Arditi M, Proc Natl Acad Sci USA 2004 101 10679 10684 10.1073/pnas.0403249101 15249654 (Pubitemid 38955802)
32. Tenascin-C produced by oxidized LDL-stimulated macrophages increases foam cell formation through toll-like receptor-4. Liu R, He Y, Li B, Liu J, Ren Y, Han W, Wang X, Zhang L, Mol Cells 2012 34 35 41 10.1007/s10059-012-0054-x 22699754
33. Toll-like receptor 4 is up-regulated by mTOR activation during THP-1 macrophage foam cells formation. Yu M, Kang X, Xue H, Yin H, Acta biochimica et biophysica Sinica 2011 43 940 947 10.1093/abbs/gmr093 22015781
34. TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading. Pols TW, Nomura M, Harach T, Lo Sasso G, Oosterveer MH, Thomas C, Rizzo G, Gioiello A, Adorini L, Pellicciari R, Cell metabolism 2011 14 747 757 10.1016/j.cmet.2011.11.006 22152303
35. Notch signal suppresses TLR-triggered inflammatory responses in macrophages by inhibiting ERK1/2-mediated NF-κB activation. Zhang Q, Wang C, Liu Z, Liu X, Han C, Cao X, Li N, J Biol Chem 2012 287 6208 6217 10.1074/jbc.M111.310375 22205705